Juno Therapeutics, Inc. (NASDAQ:JUNO) recovered 258.73% of its value since hitting low of $17.52. The recent move of 4.18% gain helped the stock to close at $62.85 when trading ended on 11/24/2017. At recent session, the prices were hovering between $60.46 and $63.33. This company shares are -11.63% up from its target price of $55.54 and the current market capitalization stands at $7.07B. The recent change has given its price a 30.84% lead over SMA 50 and 2.05% lead over its 52-week high. The stock witnessed 45.96% gains, 104.52% gains and 169.74% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JUNO’s volatility during a week at 3.89% and during a month it has been found around 6.25%.Juno Therapeutics, Inc. (JUNO) Top Holders
Institutional investors currently hold around $4.86 billion or 83.8% in JUNO stock. Look at its top three institutional owners. Baillie Gifford & Co owns $654.48 million in Juno Therapeutics, Inc., which represents roughly 9.26% of the company’s market cap and approximately 13.46% of the institutional ownership. Similar statistics are true for the second largest owner, Crestline Management, Lp, which owns 9,348,799 shares of the stock are valued at $564.01 million. The third largest holder is Vanguard Group Inc, which currently holds $405.16 million worth of this stock and that ownership represents nearly 5.73% of its market capitalization.Juno Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 121 institutional holders increased their position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by some 19,320,414 shares, 76 decreased positions by 14,609,628 and 29 held positions by 46,658,325. That puts total institutional holdings at 80,588,367 shares, according to SEC filings. The stock grabbed 56 new institutional investments totaling 11,213,599 shares while 22 institutional investors sold out their entire positions totaling 2,810,992 shares.Juno Therapeutics, Inc. (NASDAQ:JUNO) Insider Trades
Multiple company employees have indulged in significant insider trading. Juno Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP & Chief Commercial Officer Azelby Robert has sold 6,666 shares of Juno Therapeutics, Inc. (JUNO) in trading session dated Nov. 02, 2017. These shares are worth $366,297 and were traded at $54.95 each. The SEC filing shows that Agarwal Sunil performed a sale of 7,285 shares. The President of R & D disposed these shares by way of transaction on Oct. 02, 2017. The company’s shares were given away at $44.76 per share worth to an income of some $326,077 on account of Agarwal Sunil.
General Counsel & Secretary, Cassidy Bernard J, sold 28,000 common shares of Juno Therapeutics, Inc. (JUNO) in the open market. In a transaction dated Sep. 14, 2017, the shares were put up for sale at an average price of $44.92, raking in a sum of $1,257,760. After this sale, 77,893 common shares of JUNO are directly owned by the insider, with total stake valued at $4,895,575.
In the transaction dated Sep. 13, 2017, the great number of shares disposed came courtesy the EVP & Chief Commercial Officer; Azelby Robert disposed a total of 12,850 shares at an average price of $44.95, amounting to approximately $577,608. The insider now directly owns 37,439 shares worth $2,353,041.Juno Therapeutics, Inc. (JUNO) Analyst Guide
Several analysts have released their opinion on Juno Therapeutics, Inc. (NASDAQ:JUNO), with 7 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.64 average brokerage recommendation.